Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]

Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian journal of cardiology 2022-12, Vol.38 (12), p.1979-1979
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1979
container_issue 12
container_start_page 1979
container_title Canadian journal of cardiology
container_volume 38
description
doi_str_mv 10.1016/j.cjca.2022.10.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2732541922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0828282X22009643</els_id><sourcerecordid>2732541922</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2442-24b403db2738bf3dd4fdefd2e3f75fb509b51ccae72ac95b293859bec492a1563</originalsourceid><addsrcrecordid>eNp9kc2KFDEUhQtRsB19AVd3OS6qTW79i5umGduRBmV-QBAJqeSWpq1O2iQ1MLt5EH0YX2WexJQ9a1cJJ-c73JuTZS85W3LG69e7pdopuUSGmIQlY-2jbME7XucNa6rH2YK12ObY4uen2bMQdoyVvGnqRfbnzHsZpz1EB_d3v-YAWEsrtZE2Xbw27kYGNY3Sw6VThuItbCajaTSWYHAergOBG2Cz_ZRzuCBFh5jU1TdnTYgBpNVwudleIZzb76Y36TH8447hnqwc4cKEH4nVk4rGWTAWVnoaY7i_-w1f0jjw4cE-wuk84qs3nFdFznndfH2ePRnkGOjFw3mSXb87u1q_z7cfN-fr1TZXWJaYY9mXrNA9NkXbD4XW5aBp0EjF0FRDX7Gur7hSkhqUqqt67Iq26npSZYeSV3Vxkp0ecw_e_ZwoRLE3QdE4SktuCiIFY1XyDjFZ8WhV3oXgaRAHb_bS3wrOxNyX2Im5LzHvMmuprwS9PUKUlrgx5EVI320VaeNJRaGd-R_-F7T2nrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2732541922</pqid></control><display><type>article</type><title>Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]</title><source>Elsevier ScienceDirect Journals</source><identifier>ISSN: 0828-282X</identifier><identifier>EISSN: 1916-7075</identifier><identifier>DOI: 10.1016/j.cjca.2022.10.008</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Canadian journal of cardiology, 2022-12, Vol.38 (12), p.1979-1979</ispartof><rights>2022 Canadian Cardiovascular Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2442-24b403db2738bf3dd4fdefd2e3f75fb509b51ccae72ac95b293859bec492a1563</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0828282X22009643$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><title>Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]</title><title>Canadian journal of cardiology</title><issn>0828-282X</issn><issn>1916-7075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc2KFDEUhQtRsB19AVd3OS6qTW79i5umGduRBmV-QBAJqeSWpq1O2iQ1MLt5EH0YX2WexJQ9a1cJJ-c73JuTZS85W3LG69e7pdopuUSGmIQlY-2jbME7XucNa6rH2YK12ObY4uen2bMQdoyVvGnqRfbnzHsZpz1EB_d3v-YAWEsrtZE2Xbw27kYGNY3Sw6VThuItbCajaTSWYHAergOBG2Cz_ZRzuCBFh5jU1TdnTYgBpNVwudleIZzb76Y36TH8447hnqwc4cKEH4nVk4rGWTAWVnoaY7i_-w1f0jjw4cE-wuk84qs3nFdFznndfH2ePRnkGOjFw3mSXb87u1q_z7cfN-fr1TZXWJaYY9mXrNA9NkXbD4XW5aBp0EjF0FRDX7Gur7hSkhqUqqt67Iq26npSZYeSV3Vxkp0ecw_e_ZwoRLE3QdE4SktuCiIFY1XyDjFZ8WhV3oXgaRAHb_bS3wrOxNyX2Im5LzHvMmuprwS9PUKUlrgx5EVI320VaeNJRaGd-R_-F7T2nrw</recordid><startdate>202212</startdate><enddate>202212</enddate><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202212</creationdate><title>Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2442-24b403db2738bf3dd4fdefd2e3f75fb509b51ccae72ac95b293859bec492a1563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]</atitle><jtitle>Canadian journal of cardiology</jtitle><date>2022-12</date><risdate>2022</risdate><volume>38</volume><issue>12</issue><spage>1979</spage><epage>1979</epage><pages>1979-1979</pages><issn>0828-282X</issn><eissn>1916-7075</eissn><pub>Elsevier Inc</pub><doi>10.1016/j.cjca.2022.10.008</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0828-282X
ispartof Canadian journal of cardiology, 2022-12, Vol.38 (12), p.1979-1979
issn 0828-282X
1916-7075
language eng
recordid cdi_proquest_miscellaneous_2732541922
source Elsevier ScienceDirect Journals
title Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167]
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A26%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erratum%20to%20%E2%80%9C2022%20Canadian%20Cardiovascular%20Society%20Guideline%20for%20Use%20of%20GLP-1%20Receptor%20Agonists%20and%20SGLT2%20Inhibitors%20for%20Cardiorenal%20Risk%20Reduction%20in%20Adults%E2%80%9D%20%5BCan%20J%20Cardiol%20(2022):1153-1167%5D&rft.jtitle=Canadian%20journal%20of%20cardiology&rft.date=2022-12&rft.volume=38&rft.issue=12&rft.spage=1979&rft.epage=1979&rft.pages=1979-1979&rft.issn=0828-282X&rft.eissn=1916-7075&rft_id=info:doi/10.1016/j.cjca.2022.10.008&rft_dat=%3Cproquest_cross%3E2732541922%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2732541922&rft_id=info:pmid/&rft_els_id=S0828282X22009643&rfr_iscdi=true